The rising popularity of weight loss drugs is a key reason healthcare company Eli Lilly ( LLY 1.31%) has been soaring in ...

Agency officials say a comprehensive review “found no increased risk” related to suicide among users of the GLP-1 drugs used ...

Eli Lilly is aware of this fact, which helps explain why it acquired Adverum Biotechnologies in late 2025 and just agreed to ...

Momentum in weight-loss drugs is the main reason why Eli Lilly's stock soared in 2025. Over the last five years it is up 459%, and that is excluding dividends. It is the largest drugmaker in the world ...

A more detailed review of data by the FDA showed that GLP-1 drugs do not increase the risk of suicidal ideation or behavior.

BMO analysts say Eli Lilly is well-positioned to maintain its lead in the ballooning weight loss space, predicting “strengthening leadership in obesity and beyond” as portfolios expand and patient ...

US FDA review finds no evidence linking GLP-1 receptor agonists in popular medicines like Wegovy and Zepbound to an increased ...

The request comes after a two-year review into reported links between GLP-1RAs and psychiatric adverse events.

Amgen is hoping to gain a slice of the obesity market with MariTide, which it claims has a differentiated profile to other ...

Meanwhile, the FDA has asked manufacturers of flu vaccines to update their labels to include warnings about the risk of ...

MoneyShow presents top investment ideas for 2026 from leading advisors. Part 4 includes Eli Lilly, Enterprise Products ...

At the JPMorgan Healthcare Conference in San Francisco, drugmakers signalled obesity drugs going mainstream, shifting from ...